Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 1095

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 5
Chunk 1095
---
/2033 
     —  
     —  
     —  
     — 

    Francis Knuettel II, Chief Executive Officer and Chief Financial Officer 
     27,778  
     —  
     —  
     22.68  
    5/15/2033 
     —  
     —  
     —  
     — 

    Francis Knuettel II, Chief Executive Officer and Chief Financial Officer 
     81,000  
     243,000  
     —  
     1.30  
    6/14/2024 
     —  
     —  
     —  
     — 

    Eric Lang, Chief Medical Officer 
     10,093  
     14,130  
     —  
    $22.68  
    5/15/2033 
     —  
    $—  
     —  
    $— 

    Eric Lang, Chief Medical Officer 
     32,500  
     97,500  
     —  
     1.30  
    6/14/2034 
     —  
     —  
     —  
     — 

92 

Equity
Incentive Plans

The
Channel Therapeutics Corporation 2023 Equity Incentive Plan

On
January 10, 2023, our board of directors adopted and submitted for stockholder approval the 2023 Plan, which 2023 Plan was later
approved by the Company’s stockholders. On February 15, 2023, we amended the 2023 Plan to increase the number of shares
available for issuance thereunder to 444,444 and on October 22, 2024, we further amended the 2023 Plan to increase the number
of shares available for issuance thereunder to 1,944,444. The following summary of the material features of the 2023 Plan is qualified
in its entirety by reference to the complete text of the 2023 Plan, a copy of which is filed with this Report. The 2023 Plan will
terminate on January 10, 2033, in accordance with its terms, although, awards outstanding under the 2023 Plan will continue to
be governed by their existing